X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (84) 84
humans (80) 80
male (59) 59
female (58) 58
cardiac & cardiovascular systems (57) 57
pulmonary hypertension (51) 51
middle aged (50) 50
abridged index medicus (47) 47
adult (44) 44
aged (36) 36
hypertension, pulmonary - drug therapy (36) 36
hypertension, pulmonary - physiopathology (33) 33
hypertension (29) 29
respiratory system (28) 28
therapy (24) 24
pulmonary arterial hypertension (21) 21
drug therapy (20) 20
survival (20) 20
cardiology (19) 19
double-blind method (19) 19
exercise (19) 19
treatment outcome (19) 19
care and treatment (17) 17
antihypertensive agents - therapeutic use (16) 16
hemodynamics (16) 16
disease (15) 15
exercise test (15) 15
research (15) 15
diagnosis (14) 14
double-blind (14) 14
adolescent (13) 13
cardiology and cardiovascular medicine (13) 13
cardiovascular (13) 13
hypertension, pulmonary - diagnosis (13) 13
bosentan (12) 12
follow-up studies (12) 12
pulmonary arteries (12) 12
dose-response relationship, drug (11) 11
medical colleges (11) 11
patients (11) 11
prostacyclin (11) 11
radiology, nuclear medicine & medical imaging (11) 11
ambrisentan (10) 10
critical care medicine (10) 10
heart (10) 10
physiological aspects (10) 10
prostacyclin analog (10) 10
tomography, x-ray computed (10) 10
angiography (9) 9
arterial-hypertension (9) 9
brain natriuretic peptide (9) 9
clinical trials (9) 9
controlled-trial (9) 9
exercise tolerance - drug effects (9) 9
heart failure (9) 9
mortality (9) 9
placebo-controlled trial (9) 9
studies (9) 9
usage (9) 9
aged, 80 and over (8) 8
cardiac catheterization (8) 8
continuous intravenous epoprostenol (8) 8
echocardiography (8) 8
health aspects (8) 8
peripheral vascular disease (8) 8
prognosis (8) 8
prospective studies (8) 8
scleroderma (8) 8
sitaxsentan (8) 8
tadalafil (8) 8
ultrafast computed-tomography (8) 8
antihypertensive agents - administration & dosage (7) 7
complications and side effects (7) 7
coronary artery disease - diagnostic imaging (7) 7
drug therapy, combination (7) 7
endothelin (7) 7
epoprostenol - administration & dosage (7) 7
hemodynamics - drug effects (7) 7
hemodynamics - physiology (7) 7
hypertension, pulmonary - mortality (7) 7
internal medicine (7) 7
medicine & public health (7) 7
pulmonary (7) 7
pulmonary/respiratory (7) 7
quality of life (7) 7
reproducibility (7) 7
respiratory function tests (7) 7
severity of illness index (7) 7
sildenafil (7) 7
sulfonamides - therapeutic use (7) 7
time factors (7) 7
tomography, x-ray computed - methods (7) 7
analysis (6) 6
coronary angiography - methods (6) 6
dosage and administration (6) 6
endothelin receptor antagonists (6) 6
exercise tolerance - physiology (6) 6
familial primary pulmonary hypertension (6) 6
hypertension, pulmonary (6) 6
hypertension, pulmonary - etiology (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Index Medicus | Abridged Index Medicus | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal Article
Advances in Pulmonary Hypertension, ISSN 1933-088X, 01/2018, Volume 16, Issue 4, pp. 165 - 169
Journal Article
Respiratory research, ISSN 1465-9921, 09/2019, Volume 20, Issue 1, pp. 208 - 208
Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naïve participants with pulmonary arterial... 
Index Medicus | Research | Combination therapy | Research-clinical | Pulmonary hypertension
Journal Article
Advances in Pulmonary Hypertension, ISSN 1933-088X, 01/2019, Volume 18, Issue 2, pp. 42 - 46
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 21, pp. 1971 - 1981
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 06/2008, Volume 117, Issue 23, pp. 3010 - 3019
Journal Article
Circulation, ISSN 0009-7322, 07/2013, Volume 128, Issue 5, pp. 502 - 511
Journal Article
Journal Article
Chest, ISSN 0012-3692, 08/2004, Volume 126, Issue 2, pp. 420 - 427
Journal Article
Chest, ISSN 0012-3692, 01/2009, Volume 135, Issue 1, pp. 122 - 129
Some endothelin receptor antagonists (ERAs) are associated with liver function test (LFT) result abnormalities. However, ambrisentan has an incidence of serum... 
bosentan | sulfonamide | ambrisentan | hepatotoxicity | propanoic acid | pulmonary hypertension | sitaxsentan | serum aminotransferase | endothelin receptor antagonist | liver function test | Liver function test | Bosentan | Sulfonamide | Endothelin receptor antagonist | Serum aminotransferase | Hepatotoxicity | Propanoic acid | Pulmonary hypertension | Ambrisentan | Sitaxsentan | SURVIVAL | CONTROLLED-TRIAL | EFFICACY | ATRASENTAN | SAFETY | ENDOTHELIN ANTAGONIST BOSENTAN | RECEPTOR ANTAGONIST | REFRACTORY PROSTATE-CANCER | RESPIRATORY SYSTEM | MEN | BLOCKADE | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Male | Young Adult | Phenylpropionates - therapeutic use | Adult | Female | Hypertension, Pulmonary - drug therapy | Child | Endothelin Receptor Antagonists | Hypertension, Pulmonary - enzymology | Pyridazines - therapeutic use | Liver Function Tests | Treatment Outcome | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Disease-Free Survival | Sulfonamides - therapeutic use | Adolescent | Sulfonamides - adverse effects | Transaminases - blood | Aged | Isoxazoles - therapeutic use | Isoxazoles - adverse effects | Complications and side effects | Analysis | Dosage and administration | Research | Drug therapy | Liver function tests | Index Medicus | Abridged Index Medicus
Journal Article
Chest, ISSN 0012-3692, 10/2008, Volume 134, Issue 4, pp. 40S - 40S
Journal Article